Navigation Links
Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products

CARY, N.C., April 5, 2013 /PRNewswire/ -- Covis Pharmaceuticals, Inc. announced an agreement today to distribute Nilandron® (nilutamide), Plaquenil® (hydroxychloroquine), Rilutek® (riluzole), Uroxatral® (alfuzosin hydrochloride) and Kayexalate® (sodium polystyrene sulfate) in the United States.

The products cover a broad array of treatments and disease states:  Nilandron is used to treat prostate cancer; Plaquenil is an anti-malarial drug; Rilutek treats amyotrophic lateral sclerosis; Uroxatral is used to treat Benign Prostatic Hyperplasia (BPH); and, Kayexalate is prescribed to remove dangerously high levels of potassium in the blood.  With the addition of these products, Covis Pharmaceuticals, Inc. will be distributing 11 brands in the United States.  As part of their mission to ensure availability and access to all products, Covis will continue to offer a patient assistance program

"This agreement underscores our commitment to provide patients with a continuous supply of safe and efficacious therapeutic solutions," said Bill Collins , Chief-Executive-Officer of Covis.  "These additional products will allow Covis to broaden our portfolio with consistent, top quality branded pharmaceuticals."  

The company's current product portfolio includes Lanoxin® (digoxin) Tablets, Lanoxin® (digoxin) IV, Parnate® (tranylcypromine sulfate tablets), Zantac® (ranitidine hydrochloride) Injection, Fortaz® (ceftazidime for injection) and Zinacef® (cefuroxime for injection).  For full prescribing information on these Covis products, including boxed warnings for Parnate®, please visit or contact the Company at 919-535-3049.  For full prescribing information on Nilandron Tablets, Plaquenil Tablets, Rilutek Tablets, Uroxatral Tablets, and Kayexalate Powder, including boxed warnings for Nilandron and Plaquenil, please visit

Fortaz®, Zinacef®, Lanoxin®, and Parnate® are registered trademarks of the GlaxoSmithKline group of companies. Zantac® is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc., used under license.

About Covis Pharmaceuticals, Inc.   
Covis Pharmaceuticals is a specialty pharmaceutical distributor dedicated to improving the lives of people with life-threatening conditions and chronic illnesses. It is our mission to provide our customers with a continuous supply of safe and efficacious therapeutic solutions. The Website is:

SOURCE Covis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
9. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
10. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
11. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
Breaking Medicine News(10 mins):